Human milk oligosaccharides (HMOs) represent a fascinating class of complex carbohydrates that have gained significant attention in glycoscience and infant nutrition research. As the third most abundant solid component in human breast milk after lactose and lipids, HMOs comprise a structurally diverse family of unconjugated glycans that play multifaceted roles in infant health and development. Understanding the biochemistry, biosynthesis, and biological functions of these molecules is essential for researchers, clinicians, and contract research organizations working in glycan analysis, synthesis, and therapeutic applications.
Structural Characteristics of HMOs
Basic Molecular Architecture
HMOs are short polymers consisting of 3-20 monosaccharide units built from five basic building blocks: glucose (Glc), galactose (Gal), N-acetylglucosamine (GlcNAc), fucose (Fuc), and N-acetylneuraminic acid (Neu5Ac, commonly known as sialic acid). All HMOs contain lactose (Gal-β1,4-Glc) at the reducing end, which serves as the core structure for further glycosylation. This lactose core can be elongated through the addition of lacto-N-biose (LNB, Gal-β1,3-GlcNAc, type 1 chain) or N-acetyllactosamine (LacNAc, Gal-β1,4-GlcNAc, type 2 chain) units in either linear or branched configurations.
Structural Classification
Based on their composition and modifications, HMOs can be classified into three major structural categories:
Fucosylated HMOs: These structures contain one or more fucose residues attached through α1,2-, α1,3-, or α1,4-glycosidic linkages. The most abundant HMO in human milk is 2′-fucosyllactose (2′-FL), which can constitute up to 30% of total HMO content at approximately 3 g/L. Fucosylated HMOs include Lewis antigens and blood group-related structures.
Sialylated HMOs: These molecules contain sialic acid residues linked through α2,3- or α2,6-glycosidic bonds. Representative structures include 3′-sialyllactose (3′-SL) and 6′-sialyllactose (6′-SL), which are among the simplest sialylated HMOs.
Neutral core HMOs: These non-fucosylated, non-sialylated structures consist of lactose elongated with lacto-N-biose or N-acetyllactosamine units. Examples include lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT).
Figure 1. Classification of most common HMOs. Extracted from Duman, H.; Bechelany, M.; Karav, S. Human Milk Oligosaccharides: Decoding Their Structural Variability, Health Benefits, and the Evolution of Infant Nutrition. Nutrients 2025, 17 (1), 118. https://doi.org/10.3390/nu17010118.
To date, more than 160 distinct HMO structures have been characterized, demonstrating remarkable structural diversity. Asymmetric multiantennary structures with multiple branches, each potentially carrying unique glycoepitopes, add to this complexity.
Biosynthesis of HMOs
HMO biosynthesis occurs in mammary gland epithelial cells through the sequential action of specific glycosyltransferases. These enzymes catalyze the transfer of monosaccharides from activated nucleotide-sugar donors—such as guanosine diphosphate fucose (GDP-Fuc), cytidine monophosphate sialic acid (CMP-Neu5Ac), and uridine diphosphate galactose/N-acetylglucosamine (UDP-Gal/UDP-GlcNAc)—to acceptor oligosaccharides.
Key glycosyltransferases involved in HMO synthesis include:
- Fucosyltransferases (FUTs): FUT2 (secretor gene) catalyzes α1,2-fucosylation and is essential for producing 2′-FL, while FUT3 and FUT5 add fucose in α1,3- and α1,4-linkages to create Lewis epitopes.
- Sialyltransferases (STs): ST3GAL enzymes (particularly ST3GAL3, ST3GAL4, and ST3GAL6) add sialic acid in α2,3-linkages, while ST6GAL1 catalyzes α2,6-sialylation.
- β1,3-N-acetylglucosaminyltransferases (B3GNTs): These enzymes extend oligosaccharide chains by forming type 1 structures.
- β1,6-N-acetylglucosaminyltransferase (GCNT2): This enzyme introduces branching points by adding β1,6-linked GlcNAc to internal galactose residues, enabling the formation of bi- and triantennary structures.
Biological Functions and Mechanisms of Action
Prebiotic Effects and Microbiome Modulation
Unlike most milk components that are digested and absorbed in the small intestine, HMOs are largely resistant to hydrolysis by human digestive enzymes and reach the colon intact. There, they serve as selective substrates for beneficial gut bacteria, particularly Bifidobacterium species, which possess specialized glycosidases and transport systems for HMO utilization. This selective enrichment of bifidobacteria helps establish a healthy gut microbiota composition in infants, promoting colonization resistance against pathogens.
Anti-Adhesive and Antimicrobial Properties
HMOs function as soluble decoy receptors that mimic glycan structures on intestinal epithelial cell surfaces. Many pathogenic bacteria and viruses recognize and bind to specific glycan epitopes on host cells as the initial step in infection. By presenting similar structures, HMOs competitively inhibit pathogen adhesion to the gut mucosa, thereby reducing the risk of gastrointestinal and respiratory infections. This mechanism has been demonstrated for various pathogens including norovirus, Norwalk virus, rotavirus, influenza virus, respiratory syncytial virus (RSV), and enteropathogenic bacteria.
Immunomodulatory Functions
HMOs exert direct effects on immune system development and function through multiple mechanisms. They modulate immune cell populations, including T lymphocytes and regulatory T cells, and influence the balance between pro-inflammatory Th1 and anti-inflammatory Th2 responses. Specific HMOs reduce the production of pro-inflammatory cytokines while maintaining appropriate immune surveillance.
Clinical studies have demonstrated that HMO supplementation in infant formula increases secretory IgA levels, reduces markers of intestinal inflammation such as α-1-antitrypsin and calprotectin, and decreases the incidence of infections requiring medical intervention. HMOs also interact with pattern recognition receptors and G-protein coupled receptors (GPCRs) on immune cells, modulating inflammatory signaling pathways including TLR4/NF-κB.
Impact on Intestinal Barrier Function and Beyond
HMOs promote maturation of the intestinal epithelium and strengthen barrier function by influencing glycocalyx composition and tight junction integrity. Emerging evidence suggests additional systemic effects, as HMOs and their metabolites can be absorbed into circulation and detected in infant serum and urine. Preclinical studies indicate potential roles in neurocognitive development, with specific HMOs influencing brain sialylation patterns and synaptic plasticity.
Figure 2. Summary of the beneficial applications of HMOs in the digestive tract of infants. Extracted from Walsh, C.; Lane, J. A.; van Sinderen, D.; Hickey, R. M. Human Milk Oligosaccharides: Shaping the Infant Gut Microbiota and Supporting Health. J. Funct. Foods 2020, 72, 104074. https://doi.org/10.1016/j.jff.2020.104074.
Analytical Characterization
Characterizing the structural complexity of HMOs requires sophisticated analytical platforms. State-of-the-art approaches combine high-performance liquid chromatography (HPLC), particularly hydrophilic interaction chromatography (HILIC), with high-resolution mass spectrometry (MS) and tandem MS (MS/MS) for accurate identification and quantitation. In Asparia we specialize in Glycan Analysis and offer our services to a broad range of partners, including:
- Academic and Research Institutions: Assisting with fundamental biological studies and biomarker discovery related to glycans.
- Biotechnology and Pharmaceutical Companies: Supporting the development of glycoconjugate therapeutics, biosimilars, and novel nutritional products.
- Food and Nutraceutical Industries: Providing analysis for quality control and R&D of functional ingredients, particularly those involving human milk oligosaccharides (HMOs) or other complex carbohydrates.
Our goal is to translate the complexity of glycan structures into actionable scientific data for your project.
Conclusion
Human milk oligosaccharides represent a paradigm of nature’s molecular sophistication, serving as prebiotics, antimicrobials, immunomodulators, and developmental signals that collectively support infant health. The structural diversity of HMOs, arising from combinatorial biosynthetic pathways involving multiple glycosyltransferases, creates a complex glycan landscape with structure-specific biological activities. Advances in industrial fermentation technology and analytical glycomics have enabled the production and characterization of individual HMOs at scale, facilitating clinical research and commercial applications.
As the field progresses toward synthesizing more complex HMO structures and elucidating mechanisms underlying their diverse biological effects, opportunities expand for therapeutic interventions beyond infant nutrition. Contract research organizations providing expertise in glycan synthesis, structural characterization, and functional analysis will play essential roles in advancing HMO research and translating discoveries into clinical applications. The continued investigation of HMOs exemplifies how fundamental glycoscience research can yield practical benefits for human health across the lifespan.
References
(1) Corona, L.; Lussu, A.; Bosco, A.; Pintus, R.; Cesare Marincola, F.; Fanos, V.; Dessì, A. Human Milk Oligosaccharides: A Comprehensive Review towards Metabolomics. Children 2021, 8 (9), 804. https://doi.org/10.3390/children8090804.
(2) Jacobs, J. P.; Lee, M. L.; Rechtman, D. J.; Sun, A. K.; Autran, C.; Niklas, V. Human Milk Oligosaccharides Modulate the Intestinal Microbiome of Healthy Adults. Sci. Rep. 2023, 13 (1), 14308. https://doi.org/10.1038/s41598-023-41040-5.
(3) Walsh, C.; Lane, J. A.; van Sinderen, D.; Hickey, R. M. Human Milk Oligosaccharides: Shaping the Infant Gut Microbiota and Supporting Health. J. Funct. Foods 2020, 72, 104074. https://doi.org/10.1016/j.jff.2020.104074.
(4) Duman, H.; Bechelany, M.; Karav, S. Human Milk Oligosaccharides: Decoding Their Structural Variability, Health Benefits, and the Evolution of Infant Nutrition. Nutrients 2025, 17 (1), 118. https://doi.org/10.3390/nu17010118.